Private Trust Company
BCAX icon

Private Trust Company’s Bicara Therapeutics BCAX Stock Holding History

Private Trust Company’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.19K Hold
225
– – ﹤0.01% 2354
2026
Q2 		$6.68K Hold
225
– – ﹤0.01% 2214
2026
Q1 		$4.48K Hold
225
– – ﹤0.01% 2222
2025
Q4 		$3.79K Hold
225
– – ﹤0.01% 2235
2025
Q3 		$3.55K Buy
+225
New +$2.52K ﹤0.01% 2234

Other funds holding BCAX

Red Tree Management
Red Tree Management Redwood City, California $117M AUM 89.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Nan Fung Trinity
Nan Fung Trinity Central, Hong Kong, Hong Kong $1.04B AUM 32.17% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
SEB Asset Management
SEB Asset Management Stockholm $27B AUM
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
NTIC
Napean Trading & Investment Company Singapore $232M AUM 24.75% 1-Year Est. Return

Private Trust Company's BCAX Position: Q3 2026 in Review

Private Trust Company held its Bicara Therapeutics (BCAX) position steady in Q3 2026 at 225 shares worth $4.19K. The position accounts for ﹤0.01% of the portfolio, ranked #2354.

Private Trust Company first reported a position in BCAX in Q3 2025 and has held it in 5 quarters since. The position peaked at $6.68K in Q2 2026. 49 funds tracked by Wall St. Rank hold BCAX as of Q3 2026.

  • Private Trust Company held 225 shares of Bicara Therapeutics worth $4.19K as of Q3 2026.
  • Private Trust Company left its Bicara Therapeutics share count unchanged in Q3 2026.
  • Bicara Therapeutics made up ﹤0.01% of Private Trust Company's portfolio in Q3 2026, its #2354 holding.
  • Private Trust Company first reported a position in Bicara Therapeutics in Q3 2025 and has held it in 5 quarters since.
  • Private Trust Company's Bicara Therapeutics position peaked at $6.68K in Q2 2026.
  • 49 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q3 2026.

Based on Private Trust Company's 13F filing for Q3 2026, filed 20 Oct 2026.